The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S25-S29 , February 2004

Molecular Epidemiology of Androgen-Metabolic Loci in Prostate Cancer: Predisposition and Progression

  • NICK M. MAKRIDAKIS
    • ,
  • JUERGEN K.V. REICHARDT

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Biochemistry and Molecular Biology, Institute for Genetic Medicine, USC Keck School of Medicine, 2250 Alcazar St., Los Angeles, California 90089-9075 (telephone: 323-442-1529; FAX: 323-442-2764.
    • Supported by grants from the NCI (CA68581 and CA83112), Department of Defense (PC992018) and California Cancer Research Program (99-0053V-10150).

REFERENCES 

  1. Jemal A , Murray T , Samuels A , Ghafoor A , Ward E , Thun MJ . Cancer statistics, 2003 . CA Cancer J Clin . 2003;53:5
  2. Black RJ , Bray F , Ferlay J , Parkin DM . Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990 . Eur J Cancer . 1997;33:1075
  3. Huggins C , Hodges CV . Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res . 1941;1:293
  4. SEER . Cancer incidence and mortality in the United States, 1973–1981 . Bethesda, Maryland: U.S. Department of Health and Human Services; 1984;
  5. Bernstein L , Ross RK . Cancer in Los Angeles County, A Portrait of Incidence and Mortality . Los Angeles, California: University of Southern California and the California Tumor Registry, Department of Health Services, State of California; 1991;
  6. Brawley OW , Knopf K , Merrill R . The epidemiology of prostate cancer part I: descriptive epidemiology . Sem Urol Oncol . 1998;16:187
  7. Carter BS , Bova GS , Beaty TH , Steinberg GD , Childs B , Isaacs WB , et al.   Hereditary prostate cancer: epidemiologic and clinical features . J Urol . 1993;150:797
  8. Simard J , Dumont M , Soucy P , Labrie F . Perspective: prostate cancer susceptibility genes . Endocrinology . 2002;143:2029
  9. Cheng E , Lee C , Grayhack J . Endocrinology of the prostate . In:  Lepor H ,  Lawson RK editor. Prostate Diseases . Philadelphia: W. B. Saunders Co.; 1993;p. 57–71
  10. Russell DW , Wilson JD . Steroid 5α-reductase: two genes/two enzymes . Annu Rev Biochem . 1994;63:25
  11. Barrack ER . Androgen receptor mutations in prostate cancer . Mt Sinai J Med . 1996;63:403
  12. Chen C , Lamharzi N , Weiss NS , Etzioni R , Dightman DA , Barnett M , et al.   Androgen receptor polymorphisms and the incidence of prostate cancer . Cancer Epidemiol Biomarkers Prev . 2002;11:1033
  13. Tut TG , Ghadessy FJ , Trifiro MA , Pinsky L , Yong EL . Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production, and male infertility . J Clin Endocrinol Metab . 1997;82:3777
  14. Visakorpi T , Hyytinen E , Koivisto P , Tanner M , Keinanen R , Palmberg C , et al.   In vivo amplification of the androgen receptor gene and progression of human prostate cancer . Nat Genet . 1995;9:401
  15. Marcelli M , Ittmann M , Mariani S , Sutherland R , Nigam R , Murthy L , et al.   Androgen receptor mutations in prostate cancer . Cancer Res . 2000;60:944
  16. Gottlieb B , Beitel LK , Lumbroso R , Pinsky L , Trifiro M . Update of the androgen receptor gene mutations database . Hum Mutat . 1999;14:103
  17. Syvanen AC , Landegren U , Isaksson A , Gyllensten U , Brookes A . First International SNP Meeting at Skokloster, Sweden, August 1998. Enthusiasm mixed with scepticism about single-nucleotide polymorphism markers for dissecting complex disorders . Eur J Hum Genet . 1999;7:98
  18. Makridakis NM , Ross RK , Pike MC , Crocitto LE , Kolonel LN , Pearce CL , et al.   Association of mis-sense substitution in the SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA . Lancet . 1999;354:975
  19. Jaffe JM , Malkowicz SB , Walker AH , MacBride S , Peschel R , Tomaszewski J , et al.   Association of SRD5A2 genotype and pathological characteristics of prostate tumors . Cancer Res . 2000;60:1626
  20. Margiotti K , Sangiuolo F , de Luca A , Froio F , Pearce CL , Ricci-Barbini V , et al.   Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients . Dis Markers . 2000;16:147
  21. Soderstrom T , Wadelius M , Andersson SO , Johansson JE , Johansson S , Granath F , et al.   5alpha-reductase 2 polymorphisms as risk factors for prostate cancer . Pharmacogenetics . 2002;12:307
  22. Hsing AW , Chen C , Chokkalingam AP , Gao YT , Dightman DA , Nguyen HT , et al.   Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study . Cancer Epidemiol Biomarkers Prev . 2001;10:1077
  23. Mononen N , Ikonen T , Syrjakoski K , Matikainen M , Schleutker J , Tammela TL , et al.   A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland . Br J Cancer . 2001;84:1344
  24. Makridakis N , Ross RK , Pike MC , Chang L , Stanczyk FZ , Kolonel LN , et al.   A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase . Cancer Res . 1997;57:1020
  25. Makridakis NM , di Salle E , Reichardt JK . Biochemical and pharmacogenetic dissection of human steroid 5α-reductase type II . Pharmacogenetics . 2000;10:407
  26. Thompson IM , Coltman CA , Crowley J . Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial . Prostate . 1997;33:217
  27. Akalu A , Dlmajian DA , Highshaw RA , Nichols PW , Reichardt JK . Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression . J Urol . 1999;161:1355
  28. Labrie F , Simard J , Luu-The V , Bélanger A , Pelletier G . Structure, function and tissue-specific gene expression of 3beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues . J Steroid Biochem Mol Biol . 1992;43:805
  29. Berube D , Luu-The V , Lachance Y , Gagne R , Labrie F . Assignment of the human 3B-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1 . Cytogenet Cell Genet . 1989;52:199
  30. Verreault H , Dufort I , Simard J , Labrie F , Luu-The V . Dinucleotide repeat polymorphisms in the HSD3B2 gene . Hum Mol Genet . 1994;3:384
  31. Devgan SA , Henderson BE , Yu MC , Shi CY , Pike MC , Ross RK , et al.   Genetic variation of 3beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk . Prostate . 1997;33:9
  32. Lunn RM , Bell DA , Mohler JL , Taylor JA . Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) . Carcinogenesis . 1999;20:1727
  33. Wadelius M , Andersson AO , Johansson JE , Wadelius C , Rane E . Prostate cancer associated with CYP17 genotype . Pharmacogenetics . 1999;9:635
  34. Stanford GL , Noonan EA , Iwasaki L , Kolb S , Chadwick RB , Feng Z , et al.   A polymorphism in the CYP17 gene and risk of prostate cancer . Cancer Epidemiol Biomarkers Prev . 2002;11:243
  35. Geissler WM , Davis DL , Wu L , Bradshaw KD , Patel S , Mendonca BB , et al.   Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 . Nat Genet . 1994;7:34
  36. Montie JE , Pienta KJ . Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer . Urology . 1994;43:892
  37. Ekman P . Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts . Eur Urol . 1999;35:362

 Submitted for publication September 29, 2004.For other articles on a related topic see pages 322 and 328.

PII: S0022-5347(05)62514-1

doi: 10.1097/01.ju.0000107844.78769.35

The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S25-S29 , February 2004

Article Tools